lower (2.4% vs 6.4% of the study population) and that the rate of AMI was ϳ13-fold lower (5.4% vs 72%) compared with the population studied by Christenson et al. (1) . This was expected, because 58% had severe ST-segment elevation in the GUSTO IIa study, compared with Ͻ10% with only transient elevations in the TIMI IIIB study. Given the lower overall risk of the TIMI IIIB population, the ability to identify candidates at high risk of an acute coronary event is important because, typically, patients with unstable angina are not monitored as rigorously as patients who have a confirmed AMI. The ability to stratify and closely monitor such a subpopulation during this interval of heightened risk will likely have impact on the morbidity and mortality of unstable angina patients who progress to AMI.
Finally, a recent paired study used both point-of-care qualitative and laboratory-based quantitative tests for cTnT and cTnI to assess the efficacy of initial diagnosis and shortterm risk stratification based on marker concentrations at presentation (7) . Of 773 patients presenting to an emergency department, 171 were positive for cTnI and 123 were positive for cTnT. Among 47 patients with AMI that evolved while at the hospital, 94% were positive for cTnT and 100% were positive for cTnI. Among 315 patients with unstable angina, 70 patients were positive for cTnT (22%) and 114 were positive for cTnI (36%). During 30 days of followup, 34 cardiac events were reported, 20 fatal and 14 nonfatal AMIs. Of these, 20% of the deaths (4 of 20) had a negative cTnT result and only 5% (1 of 20) had a negative cTnI result. Of the nonfatal AMI patients, 21% (3 of 14) had negative cTnT values and 7% (1 of 14) had negative cTnI values. As predictors of a cardiac event at 30 days, both assays were highly significant predictors regardless of the ECG value; however, the odds ratio for cTnI was Ͼ2.4-fold that of cTnT. The authors' conclusions were exactly the opposite of Christenson et al. (1) , i.e., cTnI is slightly more sensitive than cTnT.
At this stage in the evolution of understanding of how to best utilize cTnT and cTnI results, on balance, careful analysis of the literature suggests that both proteins are about comparable in terms of initial diagnosis of AMI and prediction of shortterm cardiac events. Selection of one assay vs the other may therefore be made more on the basis of convenience, system availability, and analytical rather than clinical performance. Additional well-controlled studies with a primary objective of direct cardiac marker comparisons similar to that of Hamm et al. (7) are required to determine if cTnI or cTnT is truly the better marker. Any assessment of the utility of troponins in assigning predictive value must clarify the status of the unstable angina/ non-Q wave myocardial infarction population because they are the most problematic to diagnose and manage. In that regard, cTnI data from the TIMI IIIB study (2, 6) provide convincing evidence of the utility of cTnI in risk stratification. Similar comprehensive studies on unstable angina/non-Q wave myocardial infarction are required of cTnT to assure comparability.
Barry Bluestein * George Parsons Kimberly Foster Chiron Diagnostics Corporation
333 Coney Street East Walpole, MA 02032 *Author for correspondence.
Another reader comments on the same article:
To the Editor: I commend Christenson et al. (1) for performing analysis of both cardiac troponin T (cTnT) and I (cTnI) in a large population of patients with acute coronary syndromes to compare the abilities of these cardiac markers to stratify risk. I'd like to comment on three points regarding findings from this paper. First, one issue that should be addressed more rigorously by the authors involves the 1.5 g/L cTnI (Stratus) cutoff concentration used for predicting clinical outcomes. Although it is true that the Dade Stratus ® package insert states an upper reference limit for acute myocardial infarction as 1.5 g/L, the 97.5 percentile of the distribution of 150 individuals presenting with chest pain but subsequently diagnosed as non-acute myocardial infarction was 0.6 g/L. Thus, 0.6 g/L should be the cutoff value used for comparison with the cTnT cutoff value of 0.1 g/L, which is the upper reference limit established in clinical trial studies for cTnT ((2); Christenson et al. reference 24). If the authors were to establish for themselves appropriate cutoff concentrations using ROC curve analyses using the same population of patients, they would find that the Stratus cTnI cutoff of 1.5 g/L corresponds to a cTnT cutoff of 0.2 g/L and that a cTnI cutoff of 0.6 g/L corresponds to a cTnT value of 0.1 g/L (unpublished results from our laboratory). Thus, it would be of value to report the cTnI concentrations of the 66 patients who were cTnT-positive and cTnI-negative in their study (1) .
Second, all samples were frozen after collection for 12-18 months prior to cTnI analysis. However, cTnT analysis was performed within 60 days after collection. Unfortunately, no data are given in the paper by Finally, the authors note several times in their discussion that differences in the release patterns of cTnT and cTnI, with cTnT being released earlier, are a rationale for why cTnT shows favorable results. However, none of the references cited in their paper actually compare these two markers. In a study of acute myocardial infarction patients in which hourly cTnT and cTnI measurements were followed during the first 6 h after admission, no statistical differences in release patterns were observed (4). Furthermore, this study (4) also demonstrates equivalent early release of troponin and creatine kinase (CK) MB mass, and does not support an early increase of cTnT compared to CK-MB, as noted by Christenson et al. (1) .
In conclusion, because these investigators will continue to make valuable contributions to this clinically important area, it is extremely important that they establish in their own laboratories, using identical patient populations, statistically derived decision cutoffs, so that fewer questions are raised when cTnT and cTnI concentrations are compared in risk stratification studies in patients with acute coronary syndromes.
Fred S. Apple

Department of Laboratory Medicine and Pathology Hennepin County Medical Center 701 Park Ave. Minneapolis, MN 55415
Fax 612-904-4229 E-mail fred.apple@co.hennepin.mn.us
Two of the authors of the article cited in the two preceding letters respond:
To the Editor:
We appreciated the comments of Drs. Bluestein and Apple regarding our recent paper comparing cardiac troponin T (cTnT) and cardiac troponin I (cTnI) for risk stratification (1). Because their comments addressed similar issues, the following represents our responses to both communications.
One issue raised involved the significance (P ϭ 0.0375) of differences between the ROC curve areas. The comparison of ROC curve areas has been commonly performed in laboratory medicine to evaluate the relative usefulness of tests. Such comparison provides practical information for partly meeting this objective, so long as method limitations such as the shapes of the curves and the tradeoff of sensitivity and specificity are recognized. It must also be remembered that the ROC statistical method is akin to the Wilcoxon test, so the reader must interpret differences that achieve statistical significance with regard to their practical meaning. The ROC analysis for cTnT and cTnI was included in our paper (1) for the sake of completeness, because they are a commonly utilized tool. Although the ROC data are supportive of the overall findings of the study, it is critical that these data be considered in light of the logistic regression analysis.
The issue of which cutoff is appropriate for use with the Stratus cTnI assay was raised. In our study, a cTnI cutoff of 1.5 g/L and a cTnT cutoff of 0.1 g/L were used, because this was the information provided for the diagnosis of myocardial infarction (MI) in the respective manufacturers' inserts. Unfortunately, data supporting the 1.5 g/L cutoff in the Stratus cTnI package insert have never been published in the peer-reviewed literature. Institution-specific data were quoted, from which it was summarized that a 0.6 g/L Stratus cTnI value correlates with a 0.1 g/L cTnT result and that 1.5 g/L from Stratus would correlate with a 0.2 g/L for cTnT. Other anecdotal cutoffs for MI that I have been told for the Stratus cTnI system are any detectable amount (Ͼ0.35), 0.8, 1.2, and as high as 3.2 g/L! In total, this information underscores the difficulty (folly) of selecting comparative cutoffs without carefully defined protocols designed to compensate for the assays, patient populations, different institutions located in diverse geographic locations, and different philosophies of (and reimbursement for) medical practice. Readers must be keenly aware of the issues of cutoffs when reading this or any other paper. Most importantly, readers must focus on the body of our paper (1), which examines cTnT and cTnI as continuous variables with logistic regression analysis, a strategy that altogether avoids the caveats (and possible bias) of cutoffs.
Obviously the concept and caveats of cutoffs are impossible to avoid when using positive/negative qualitative tests, as was done comparing rapid assays for cTnI and cTnT in the study of Hamm et al. (2) . To compare our study (1) with that of Hamm et al. (2) is inappropriate because the tests run in the latter were both qualitative and therefore could not be treated as continuous variables. Suffice it to say that readers need to keep in mind that that our paper (1) compared two markers, cTnT and cTnI, whereas the paper of Hamm et al. compared two tests, a qualitative rapid assay for cTnI (Spectral Diagnostics) and the cTnT Rapid Assay (Boehringer Mannheim Corp.). When reading the study of Hamm et al. (2) , one should be cognizant of the relative concentrations of cTnI or
